Clinical Trials Logo

Carcinoma, Non-Small-Cell Lung clinical trials

View clinical trials related to Carcinoma, Non-Small-Cell Lung.

Filter by:

NCT ID: NCT05826366 Active, not recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Start date: June 2, 2023
Phase:
Study type: Observational

To collect information of safety in patients with unresectable advanced or recurrent non-small cell lung cancer who receive combination therapy of IMJUDO, IMFINZI and other platinum-based anti-cancer agents under actual use in the postmarketing setting.

NCT ID: NCT05825625 Recruiting - Clinical trials for Non-small Cell Lung Cancer

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Start date: May 26, 2023
Phase: Phase 2
Study type: Interventional

Prospective, non-randomized, open-label, single-arm phase II trial to investigate the feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as neoadjuvant and adjuvant treatment for surgical NSCLC patients.

NCT ID: NCT05822284 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

Start date: April 2023
Phase:
Study type: Observational

The goal of this observational study is to explore whether ctDNA-MRD dynamic monitoring can more effectively predict the therapeutic effect of induction chemoimmunotherapy followed by surgery or non-surgical treatment for stage IIIB-C driver-negative NSCLC in the MDT model, so as to accurately guide clinical diagnosis and treatment.

NCT ID: NCT05821933 Recruiting - NSCLC Clinical Trials

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Start date: September 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

an open, single-arm, multicenter phase Ib/II study

NCT ID: NCT05819346 Recruiting - Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

Digital Lifestyle Intervention for Lung Cancer Survivors After Inpatient Rehabilitation

QUALUCA
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to assess the efficacy of a digital lifestyle intervention in non-small cell lung cancer (NSCLC) survivors following inpatient rehabilitation on health-related quality of life (HRQoL) over three months.

NCT ID: NCT05818449 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer Stage IV

Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)

DigiNet
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promotes the transfer of the latest scientific knowledge into standard care. The DigiNet project is based on the established precision medicine program, the National Network Genomic Medicine Lung Cancer (nNGM) in Germany, whereby every patient receives molecular diagnostics and personalized therapy information after the initial diagnosis. Within the framework of the DigiNet project, specialized academic centers will be digitally connected with practitioners via a shared project database. Furthermore, a committee of experts will monitor the course of treatment and will advise the practitioners in case of critical conditions. Additionally, patient-reported outcomes will be incorporated into the treatment.

NCT ID: NCT05816499 Active, not recruiting - NSCLC Stage IV Clinical Trials

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

AK104IIT018
Start date: February 16, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies how well cadonilimab combined with anlotinib and docetaxel work in treating patients with non-small cell lung cancer that is stage IV or has come back. Cadonilimab, a PD-1/CTLA-4 bispecific antibody, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Anlotinib can regulate tumor microenvironment. Docetaxel was used in standard of care chemotherapy for non-small cell lung cancer, work to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cadonilimab, anlotinib and docetaxel together may work better in treating patients with non-small lung cancer compared to standard of care.

NCT ID: NCT05816252 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Start date: April 19, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.

NCT ID: NCT05815407 Completed - Clinical trials for Non Small Cell Lung Cancer

Expressiona and Diagnostic Potential of miRNAs in NSCLC

Start date: September 1, 2018
Phase:
Study type: Observational

Its to explore the expression pattern, diagnostic and prognostic potentials of miRs (106b-5p, 601 and 760) in serum of NSCLC patients

NCT ID: NCT05815186 Withdrawn - Clinical trials for Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Start date: April 2024
Phase: Phase 2
Study type: Interventional

Study record has been combined with NCT05815173. See NCT05815173 for summary.